MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia

Vargová, Karin; Pešta, Michal; Obrtlíková, Petra; Dusilkova, Nina; Minarík, L; Vargova, Jarmila; Berkova, Adela; Zemanová, Zuzana; Michalová, K; Špaček, Martin; Trněný, Marek; Stopka, Tomáš

doi:10.1038/bcj.2017.63

Cited by 16 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MiR-155 is evolutionarily conserved, and as an inhibitor of lineage differentiation, it is one of the most critical regulators of posttranscriptional gene expression in B cells[ 101 , 102 ]. It has also been confirmed to be associated with pathogenesis, aggressiveness and progression in CLL[ 103 , 104 ]; poor survival in adult and pediatric AML[ 105 ]; and poor clinical prognosis in Hodgkin's lymphomas[ 106 ] and B-cell-type Diffuse large B-cell lymphoma[ 107 , 108 ]. El-Khazragy et al[ 109 ] tried to connect the upregulation of miRNA-155a and miRNA-181a expression to ALL outcome.…”

Section: Role Of Microrna In Outcome Predictionmentioning

confidence: 99%

Role of microRNA dysregulation in childhood acute leukemias: diagnostics, monitoring and therapeutics: A comprehensive review

Szczepanek

2020

WJCO

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are short noncoding RNAs that regulate the expression of genes by sequence-specific binding to mRNA to either promote or block its translation; they can also act as tumor suppressors ( e.g ., let-7b, miR-29a, miR-99, mir-100, miR-155, and miR-181) and/or oncogenes ( e.g ., miR-29a, miR-125b, miR-143-p3, mir-155, miR-181, miR-183, miR-196b, and miR-223) in childhood acute leukemia (AL). Differentially expressed miRNAs are important factors associated with the initiation and progression of AL. As shown in many studies, they can be used as noninvasive diagnostic and prognostic biomarkers, which are useful in monitoring early stages of AL development or during therapy ( e.g ., miR-125b, miR-146b, miR-181c, and miR-4786), accurate classification of different cellular or molecular AL subgroups ( e.g ., let-7b, miR-98, miR-100, miR-128b, and miR-223), and identification and development of new therapeutic agents ( e.g ., mir-10, miR-125b, miR-203, miR-210, miR-335). Specific miRNA patterns have also been described for commonly used AL therapy drugs ( e.g ., miR-125b and miR-223 for doxorubicin, miR-335 and miR-1208 for prednisolone, and miR-203 for imatinib), uncovering miRNAs that are associated with treatment response. In the current review, the role of miRNAs in the development, progression, and therapy monitoring of pediatric ALs will be presented and discussed.

show abstract

Section: Role Of Microrna In Outcome Predictionmentioning

confidence: 99%

Role of microRNA dysregulation in childhood acute leukemias: diagnostics, monitoring and therapeutics: A comprehensive review

Szczepanek

2020

WJCO

View full text Add to dashboard Cite

show abstract

“…Hence, specific miRNAs in liquid biopsies have the potential to diagnose a variety of diseases. For example, miRNA‐155 in blood samples from DLBCL was significantly increased as compared with healthy controls, 29,30 and similar miR‐155 upregulation was also shown in CLL patients 31 . A separate cohort study, including MM patients and healthy controls, showed that the upregulated expression of miRNA‐99b was caused by t(4;14) translocation, and patients with higher levels of miRNA‐20a or miRNA‐148a are more likely to relapse 32 .…”

Section: Components Of Blood Biopsymentioning

confidence: 70%

“…Varied concentration [22][23][24][25][26][27][28] miRNA DLBCL and CLL Stable, tissue-specific No FDA-approved tests available [29][30][31][32][33][34][35] Protein-based…”

Section: Cell-based Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Liquid biopsy technologies for hematological diseases

Zhang

Khoo

2020

Medicinal Research Reviews

View full text Add to dashboard Cite

Since the discovery of circulating tumor cells in 1869, technological advances in studying circulating biomarkers from patients' blood have made the diagnosis of nonhematologic cancers less invasive. Technological advances in the detection and analysis of biomarkers provide new opportunities for the characterization of other disease types. When compared with traditional biopsies, liquid biopsy markers, such as exfoliated bladder cancer cells, circulating cell‐free DNA (cfDNA), and extracellular vesicles (EV), are considered more convenient than conventional biopsies. Liquid biopsy markers undoubtedly have the potential to influence disease management and treatment dynamics. Our main focuses of this review will be the cell‐based, gene‐based, and protein‐based key liquid biopsy markers (including EV and cfDNA) in disease detection, and discuss the research progress of these biomarkers used in conjunction with liquid biopsy. First, we highlighted the key technologies that have been broadly adopted used in hematological diseases. Second, we introduced the latest technological developments for the specific detection of cardiovascular disease, leukemia, and coronavirus disease. Finally, we concluded with perspectives on these research areas, focusing on the role of microfluidic technology and artificial intelligence in point‐of‐care medical applications. We believe that the noninvasive capabilities of these technologies have great potential in the development of diagnostics and can influence treatment options, thereby advancing precision disease management.

show abstract

“…Thus, miR-155-5p seems to play a significant role in the pathogenesis of a particular subgroup of AML patients [ 41 ]. Very recently, the dysregulation of the miR-155-5p/miR-150 network has been linked to CLL pathogenesis, as it attenuates the expression of the PU.1 proto-oncogene, a well-known regulator of differentiation in B cells [ 43 ]. Moreover, strong miR-155-5p expression was observed in CLL proliferation centers [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis

et al. 2017

View full text Add to dashboard Cite

MicroRNA-155-5p (miR-155-5p) is a proinflammatory, oncogenic miRNA, involved in various physiological processes, including hematopoiesis, immunity, inflammation, and cell lineage differentiation. It regulates important transcription factors, such as E2F2, hypoxia-inducible factor 1 (HIF1), and FOXO3. Recently, the dysregulation of miR-155-5p expression has been linked to chronic lymphocytic leukemia (CLL) pathogenesis. In this research study, we investigated the potential diagnostic and prognostic value of miR-155-5p in CLL. To achieve our goal, we isolated total RNA from peripheral blood mononuclear cells (PBMCs) collected from 88 CLL patients and 36 nonleukemic blood donors and performed polyadenylation of total RNA and reverse transcription. Next, we quantified miR-155-5p levels using an in-house-developed real-time quantitative PCR method, before proceeding to extensive biostatistical analysis. Thus, it appears that miR-155-5p is significantly overexpressed in PBMCs of CLL patients and can distinguish them from nonleukemic population. Kaplan-Meier OS analysis and bootstrap univariate Cox regression showed that high miR-155-5p expression predicts inferior OS for CLL patients (p < 0.001). Interestingly, miR-155-5p overexpression retains its unfavorable prognostic role in CLL patients stratified according to established prognostic factors [CD38 expression and mutational status of the immunoglobulin heavy chain variable region (IGHV)]. Thus, miR-155-5p appears as a promising, independent molecular biomarker of unfavorable prognosis in CLL.

show abstract

MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia

Cited by 16 publications

References 15 publications

Role of microRNA dysregulation in childhood acute leukemias: diagnostics, monitoring and therapeutics: A comprehensive review

Role of microRNA dysregulation in childhood acute leukemias: diagnostics, monitoring and therapeutics: A comprehensive review

Liquid biopsy technologies for hematological diseases

MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis

Contact Info

Product

Resources

About